Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.